Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,558
datasets available to search
ShareScore release 0.9.0
Dataset results
34,558 results for “therapy”
A Pilot Randomized Controlled Trial of Distance Laughter Therapy for Mothers' Level of Depression, Anxiety, and Parental Stress during the COVID-19 Pandemic
<p>Presented here are both quantitative and qualitative datasets from a study titled 'A Pilot Randomized Controlled Trial of Distance Laughter Therapy for Mothers’ Level of Depression, Anxiety, and Parental Stress during the COVID-19 Pandemic.' The COVID-19 pandemic has necessitated significant lifestyle modifications globally, leading to heightened psychological stressors, notably depression and anxiety. Concurrently, the exigencies of parental care have escalated, thereby amplifying the risk of caregiver exhaustion and potential child maltreatment. This study sought to assess the efficacy and feasibility of utilizing distance laughter therapy for mothers who are looking after young children during these challenging times. The primary objective was to alleviate symptoms of depression, anxiety, and parental stress.</p>
Psilocybin therapy for females with anorexia nervosa: A phase 1, open label, feasibility study
<p class="MsoNoSpacing">Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no FDA-approved medications. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (<em>m</em> BMI 19.7 kg/m<sup>2</sup>; SD 3.7) who met DSM 5 criteria for AN or pAN (partial remission) were recruited to a study conducted at an academic clinical research institute. Participants received a single 25mg dose of synthetic psilocybin combined with psychological support. The primary aim was to assess safety, tolerability, and feasibility at post-treatment via incidences and occurrences of adverse events (AEs) and clinically significant changes in: ECG, laboratory tests, vital signs and suicidality. There were no clinically significant changes in ECG, vital signs, or suicidality. Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 hours. There were no other clinically significant changes in laboratory values. All AEs were mild and transient in nature. Participants' qualitative perceptions suggest that the treatment was acceptable for most participants. <span>R</span>esults suggest that psilocybin therapy is safe, tolerable, and acceptable for female AN, a promising finding given physiological dangers and problems with treatment engagement.</p> <p class="MsoNoSpacing">ClinicalTrials.gov Identifier: NCT04661514</p>
Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa
<p><span>Retinitis pigmentosa is an inherited photoreceptor degeneration that begins with rod loss followed by cone loss. This cell loss greatly diminishes vision, with most patients becoming legally blind. Gene therapies are being developed, but it is unknown how retinal function depends on the time of intervention. To uncover this dependence, we utilize a mouse model of retinitis pigmentosa capable of artificial genetic rescue. This model enables a benchmark of best-case gene therapy by removing variables that complicate the ability to answer this vital question. Complete genetic rescue was performed at 25%, 50%, and 70% rod loss (early, mid, and late, respectively). Here we show early- and mid-treatment restores retinal function to near wild-type levels, specifically the sensitivity and signal fidelity of retinal ganglion cells, the output neurons of the retina. However, some anatomical defects persist. Late treatment retinas exhibit continued, albeit slowed, loss of sensitivity and signal fidelity among retinal ganglion cells, as well as persistent gliosis. We conclude that gene replacement therapies delivered after 50% rod loss are unlikely to restore visual function to normal. This is critical information for administering gene therapies to rescue vision.</span></p>
The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients
<p><strong>Supplementary Figure 1: </strong>Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in a sample of breast cancer patients undergoing neoadjuvant endocrine therapy.</p> <p><strong>Supplementary Figure 2: </strong>ROC curves with their respective confidence intervals and AUC values in the sample of breast cancer patients, excluding those with clinical stage IA tumors. A: ME1. B: ME2. C: ME3. D: MEm.</p> <p><strong>Supplementary Figure 3:</strong> Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in the sample of breast cancer patients undergoing neoadjuvant endocrine therapy (excluding those with clinical stage IA tumors).</p> <p> </p>
High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients
<p>High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients</p>
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
ClinicalTrials.gov study NCT01327976. IPD Sharing: NO. Countries: 2. Publications: 2.
Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
ClinicalTrials.gov study NCT03673176. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
ClinicalTrials.gov study NCT01256424. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
ClinicalTrials.gov study NCT00769379. IPD Sharing: Not stated. Countries: 4. Publications: 2.
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
ClinicalTrials.gov study NCT03930186. IPD Sharing: YES. Countries: 2. Publications: 2.
BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-
ClinicalTrials.gov study NCT00351741. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
ClinicalTrials.gov study NCT04406857. IPD Sharing: YES. Countries: 1. Publications: 1.
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
ClinicalTrials.gov study NCT01242800. IPD Sharing: YES. Countries: 5. Publications: 1.
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
ClinicalTrials.gov study NCT00490568. IPD Sharing: Not stated. Countries: 29. Publications: 1.
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
ClinicalTrials.gov study NCT04068610. IPD Sharing: YES. Countries: 5. Publications: 1.
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
ClinicalTrials.gov study NCT04669288. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
ClinicalTrials.gov study NCT00487942. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
ClinicalTrials.gov study NCT00003377. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
ClinicalTrials.gov study NCT00926575. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.